कंपनी का अवलोकन
Exagen Inc. is a specialized entity within the healthcare sector that focuses on the diagnostics and research industry, specifically designing and commercializing testing products under its AVISE brand for the United States market. The company's core function involves empowering healthcare providers to deliver comprehensive patient care through the precise diagnosis, prognosis, and ongoing monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases. This operational scope places Exagen at the intersection of medical technology and clinical utility, addressing significant needs in managing chronic and difficult-to-treat conditions. The company currently operates with a market capitalization of $74.08M and generates annual revenue of $66.58M, supported by a workforce of 216 employees. These financial figures indicate that Exagen functions as a mid-cap enterprise with a revenue base that is substantial relative to its market valuation, suggesting a company that has established a commercial presence but may still be scaling its operations to achieve profitability. The disparity between its revenue generation and market cap also highlights a valuation environment where the market is pricing in significant future growth expectations or potential risks associated with its current loss-making status.
वित्तीय स्वास्थ्य
Exagen Inc. reported a trailing twelve-month revenue of $66.58M, yet it recorded a net income of $-19,951,000 and an EBITDA of $-11,952,000, revealing a significant structural gap where operating costs and expenses far exceed gross profits. The difference between the positive revenue of $66.58M and the substantial net loss indicates a high cost structure characterized by heavy investment in R&D, commercialization efforts, or operational inefficiencies that prevent the conversion of sales into bottom-line profit. The company's free cash flow stands at $-10,364,500, which signifies a lack of financial flexibility and a reliance on external capital sources to fund ongoing operations and prevent liquidity crises. Analyzing the margin profile shows a gross margin of 58.3%, which is healthy for a diagnostics firm, but this is eroded by an operating margin of -29.9% and a profit margin of -30.0%, indicating that overhead and SG&A expenses are disproportionately high relative to sales. On the balance sheet, the company holds $32.22M in cash against $27.67M in debt, resulting in a debt-to-equity ratio of 158.55, which suggests a highly leveraged financial position despite having more cash on hand than debt owed. The current ratio of 3.45 demonstrates strong short-term liquidity, implying that the company possesses ample current assets to cover its short-term liabilities and manage daily operational obligations without immediate distress. Furthermore, the return on equity is -147.8% and the return on assets is -17.1%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized in asset deployment.
मूल्यांकन आकलन
The valuation metrics for Exagen Inc. present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -9.94, which implies that the market is not valuing the stock based on current earnings due to the lack of profitability but is instead projecting a path to future earnings recovery. The price-to-book ratio stands at 4.04, indicating that the market values the company at a significant premium over its net asset book value, likely driven by intangible assets, proprietary technology, or high growth expectations rather than tangible collateral. Alternative valuation measures such as the price-to-sales ratio of 1.11 and an EV/EBITDA of -5.82 provide additional context, suggesting that investors are willing to pay more than one dollar of sales for every dollar of revenue, despite the negative earnings multiple. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $12.23 and a 52-week low of $2.59, meaning the current price sits in a wide range that reflects extreme sentiment swings. The beta value of 1.94 indicates that the stock's price volatility is nearly double that of the broader market, making it a high-risk instrument that will amplify market movements in either direction.
Growth & Income
Exagen Inc. is experiencing robust revenue expansion with a year-over-year revenue growth rate of 21.8%, while the earnings growth rate is N/A due to the company's current unprofitable status. Since the earnings growth metric is not applicable, the company is not growing earnings faster than revenue because it has not yet achieved positive earnings, but the revenue trajectory suggests a growing top-line business model. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the payout ratio is 0.0%, indicating that all available earnings are being retained to fund operations and growth initiatives rather than being distributed to shareholders. This reinvestment strategy is typical for growth-stage biotech and diagnostic firms that prioritize market capture and product development over immediate income distribution to investors. The overall growth and income profile of Exagen Inc. is characterized by strong top-line expansion supported by a lack of current profitability and a complete absence of dividend income, positioning the stock as a pure-play growth vehicle with speculative risk characteristics.